Corporate Profile

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Aug 08
2024
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Learn More >
Aug 07
2024
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
Learn More >
Jul 31
2024
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Learn More >
Jul 01
2024
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Learn More >
Jun 20
2024
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Learn More >
May 23
2024
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Learn More >
May 13
2024
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Learn More >
May 13
2024
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Learn More >
May 06
2024
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Learn More >
Apr 26
2024
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Learn More >
View All